Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 14 Carcinoma, Non-Small-Cell Lung 13 Neoplasms 10 Glioblastoma 9 Fallopian Tube Neoplasms 8 Colorectal Neoplasms 8 Breast Neoplasms 8 Lung Neoplasms 7 Rectal Neoplasms 6 Neoplasm Metastasis 6 Gliosarcoma 6 Colonic Neoplasms 6 Carcinoma, Renal Cell 6 Brain Neoplasms 6 Prostatic Neoplasms 4 Melanoma 4 Uterine Cervical Neoplasms 3 Solitary Fibrous Tumor, Pleural 3 Sarcoma, Alveolar Soft Part 3 Sarcoma 3 Mesothelioma, Malignant 3 Carcinoma, Hepatocellular 3 Breast Neoplasms, Male 3 Advanced Solid Tumor 3 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Oligodendroglioma 2 Leukemia, Myeloid, Acute 2

Interventions

Gemcitabine 95 Cisplatin 72 Capecitabine 39 Oxaliplatin 38 durvalumab 29 Fluorouracil 27 pembrolizumab 26 Leucovorin 23 S 1 (combination) 19 Nivolumab 14 Irinotecan 14 lenvatinib 13 Bevacizumab 13 tremelimumab 10 130-nm albumin-bound paclitaxel 9 apatinib 8 Trastuzumab 7 Injections 7 Immune Checkpoint Inhibitors 7 Docetaxel 7 Albumin-Bound Paclitaxel 7 Paclitaxel 6 Drug Therapy 6 titanium silicide 5 surufatinib 5 irinotecan sucrosofate 5 gemcitabine-oxaliplatin regimen 5 envafolimab 5 camrelizumab 5 atezolizumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × cediranib × Clear all

NCT00939848 2014-10-27

ABC-03

University College, London

Phase 2/3 Completed

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡